Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258726 · ClinicalTrials.gov registry record · Phase 1
Immune Responses to Two Dose Varivax +/- MMR-II
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT00258726 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 105 participants.
The verdict
NCT00258726, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
This study will test the safety and how well the body's immune system responds to a live, but weakened varicella (chickenpox) vaccine, known as Varivax, given with and without ProQuad, another measles, mumps, rubella, and varicella virus vaccine (MMR-II). One hundred five healthy children will be enrolled in the study when they are 12 months old. All subjects will be vaccinated at 12 months of age and some subjects will receive a second vaccination at 18 months of age. All subjects will participate for 1 year. This study is a single-site, two-year trial with post-licensure vaccines.
Interventions
- BIOLOGICAL Varivax
- BIOLOGICAL MMR-II
- BIOLOGICAL Pro-Quad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258726
The ClinicalTrials.gov registry entry for NCT00258726 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Varivax is the first listed.
NCT00258726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00258726 about?
NCT00258726 is a clinical study titled "Immune Responses to Two Dose Varivax +/- MMR-II". This study will test the safety and how well the body's immune system responds to a live, but weakened varicella (chickenpox) vaccine, known as Varivax, given with and without ProQuad, another measles, mumps, rubella, and varicella virus vaccine (MMR-II). One hundred five healthy children will be en...
What is the current status of trial NCT00258726?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2005-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00258726?
The interventions under investigation include: Varivax (BIOLOGICAL), MMR-II (BIOLOGICAL), Pro-Quad (BIOLOGICAL).
Who is sponsoring clinical trial NCT00258726?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.